Amazon Great Indian Festival 2020 - Electronics
Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Amazon Great Indian Festival 2020 - Electronics
Research

| More

GSK Pharmaceuticals - Analyst call highlights - Sep 28, 2020 - ICICI Securities

Posted On: 2020-09-28 22:43:16


GlaxoSmithKline Pharmaceuticals Limited's (GSKP) held a virtual analyst meet to discuss company's performance. We cover the highlights below:

- Company believes its key brands and therapies would continue to grow over the next five years. Company has witnessed that most of its key brands have outpaced their respective industries and gained market share.

- Vaccines remains an important growth area followed by respiratory. It will also invest in therapies like oncology but that would take time to scale up. Vaccine contributes ~23% of revenue and is expected to grow in double digits. It's imported and has lower margin than the company but it would be supported by cost optimisation.

- Company has received approval for Augmentin ES600, Trelegy and Fluarix Tetra and has filed for Shingrix, Rotarix liquid oral vaccine and Nucala liquid pediatric indication to support growth over long term. In the near term it is focusing on Nucala and Menveo.

- Company has witnessed a contraction in the dermatology and anti-infective market as patients defer skin treatment and better hygiene has reduced the acute illness.

- Pandemic caused disruption at the beginning of the lockdown. Company implemented several safety protocols and work from home policy wherever possible. Gradually, ~60% of the workforce was able to achieve ~100% production. Roughly 4,000 employees are working from home. Company witnessed MoM recovery in all therapies and expect to achieve normalcy soon. Company also provided extended credits to its partners (stockists, dealers, etc.) in order to support the system.

- Company initiated several cost rationalisation steps including zero based budgeting, in order to reduce financial burden. Company is considering upskilling and redeployment in required areas for employees instead of rationalisation.

- During the lockdown company remain connected with healthcare professionals (HCPs) digitally. Ground field force quickly adapted to the new environment and digital outreach ensured business continuity. Digital medium would remain an important mode of communication and post normalisation would be an effective tool to increase its reach across the country.

- Export is not an opportunity for the company because there is a disparity between the product basket in India and other markets. Another reason is that the price disparity is too large between geographies.

- Company is considering all viable options for Vemgal plant. Company would continue to out-source some level of manufacturing and believes that they have built a strong relationship with the CMOs over time for financial viability.

- Data readout for the global trials of COVID-19 vaccine is expected by the end of the year or early next year. Currently, it's too soon for a strategy or roadmap to bring the vaccine to India. However, the opportunity remains too large to be dismissed.

Valuations and risks: GSKP's exposure only to domestic formulations, strong balance sheet and strong brand equity augurs well for the company. Recent correction has made valuations fair, hence we upgrade to HOLD from Reduce with a target price of Rs1,539/share based on 40xSep'22E EPS. Key downside risks: addition of key drugs in National List of Essential Medicines (NLEM), product concentration and government intervention. Key upside risks: better than expected performance in key products and launch of COVID-19 vaccine in India.

Shares of GLAXOSMITHKLINE PHARMACEUTICALS LTD. was last trading in BSE at Rs.1578 as compared to the previous close of Rs. 1544.1. The total number of shares traded during the day was 6279 in over 928 trades.

The stock hit an intraday high of Rs. 1589.25 and intraday low of 1530. The net turnover during the day was Rs. 9827984.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com

Amazon Great Indian Festival 2020 - Mobiles


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Havells India - Q2FY21 Result Update - ICICI Securities

Vardhman Textiles - Q2FY21 Company Update - ICICI Securities

Saregama India - Q2FY21 Company Update - ICICI Securities

Zensar Technologies - Q2FY21 Company Update - ICICI Securities

PI Industries - Q2FY21 Result Update - ICICI Securities

Derivatives Strategy - Positional Future - ICICI Securities

Grindwell Norton - Q2FY21 First Cut - ICICI Securities

Laurus Labs - Q2FY21 Result Update - ICICI Securities

Indian Oil Corporation - Q2FY21 First Cut - ICICI Securities

Mahindra Logistics - Q2FY21 First Cut - ICICI Securities

IndusInd Bank - Q2FY21 First Cut - ICICI Securities

ADD on Navin Fluorine International - EBITDA margin surprises positively! - HDFC Securities

Reiterate BUY on Larsen & Toubro - Marginal miss, bracing for recovery - HDFC Securities

US FDA tentative approval for Dapagliflozin - Zydus Cadila - Angel Broking

Maintain ADD on Radico Khaitan - Outperformance continues - HDFC Securities

Maintain REDUCE on V-Guard Industries - Muted performance continues - HDFC Securities

Cholamandalam Investment & Finance (CIFC) - Strong Set of numbers for Q2FY21 - Angel Broking

Maintain BUY on Maruti Suzuki - Festive cheer! - HDFC Securities

Can Fin Homes - Q2FY21 Result - Angel Broking

Maintain BUY on Hero Motocorp - Outperformance continues - HDFC Securities

Maintain ADD on Havells - Sharp margin recovery; Lloyd back on track - HDFC Securities

Maintain ADD on AU Small Finance Bank - Promising trends persist - HDFC Securities

Blue Star - Still not out of the woods - ICICI Securities

Larsen & Toubro - Treading cautiously - ICICI Securities

Blue Dart Express - Gross margins surprise - ICICI Securities

Gateway Distriparks - Multiple triggers at play - ICICI Securities

Piramal Enterprises - Consolidating wholesale mortgage; going LIVE with multi-asset retail lending - ICICI Securities

InterGlobe Aviation - Play on Covid recovery - ICICI Securities

Vodafone Idea Ltd - With AGR case behind, can VIL bounce back? - ICICI Securities

Power - Discom liquidity infusion scheme gains traction - ICICI Securities

Orient Cement - Higher prices, lower costs drive outperformance - ICICI Securities

Maruti Suzuki India - Quarter falls short of high expectations - ICICI Securities

PNB Housing Finance - Stress a cause of concern; business transformation a source of comfort - ICICI Securities

Gas sector - CGD draft regulations appear to favour new entrants - ICICI Securities

AU Small Finance Bank - Improving visibility on growth; progress on liability franchise gives comfort - ICICI Securities

Thyrocare Technologies - Pricing in the growth uptick - ICICI Securities

Strides Pharma Science - Steady quarter; growth to pick up - ICICI Securities

Hero MotoCorp - All eyes on the second half of festive season - ICICI Securities

Navin Fluorine International - Cashing-in new opportunities still far way - ICICI Securities

JM Financial - Measured growth, low risk tolerance to aid navigate the cycle well - ICICI Securities

Lemon Tree Hotels - Resilience amid turbulence - ICICI Securities

Larsen & Toubro Ltd - Q2FY21 Result Update - YES Securities

UTI AMC - Q2FY21 Result Update - YES Securities

VGuard Industries Ltd - Q2FY21 Result Update - YES Securities

Tata Coffee Ltd - Q2FY21 Result Update - YES Securities

AU Small Finance Bank Limited - Q2FY21 Result Update - YES Securities

Radico Khaitan Ltd - Q2FY21 Result Update - YES Securities

Can Fin Homes Limited - Q2FY21 Result Update - YES Securities

Reiterate ADD on Amara Raja Batteries - Pent-up demand leads to healthy 2Q - HDFC Securities

Maintain REDUCE on Titan - Reasonable print - HDFC Securities







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019